Unicycive Therapeutics Adjusts Annual Meeting Time for Stockholders
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is making headlines with its recent announcement concerning the timing of its upcoming Annual Meeting of Stockholders. Founded in Los Altos and recognized for its focus on kidney disease therapies, the company has revealed that the meeting will now begin at 7:00 a.m., Pacific Daylight Time. Although the date remains unchanged on June 9, those interested in participating should take note of this new time adjustment.
Understanding Unicycive's Mission
As a clinical-stage biotechnology company, Unicycive Therapeutics dedicates its efforts to developing groundbreaking treatments aimed at improving the lives of patients with kidney diseases. The company’s lead treatment involves oxylanthanum carbonate, an innovative phosphate binding agent under review by the U.S. Food and Drug Administration (FDA). This treatment is particularly significant for individuals battling hyperphosphatemia, which is a common condition among patients with chronic kidney disease undergoing dialysis.
Expansion of Treatment Portfolio
In addition to its leading investigational treatment, Unicycive is advancing its second investigational drug known as UNI-494. Designed for addressing acute kidney injury, UNI-494 has received orphan drug designation by the FDA, showcasing its potential for preventing Delayed Graft Function (DGF) in kidney transplant patients. This designation is pivotal as it indicates a recognized need in the market for effective treatments in this area.
Investor Engagement and Communication
Stockholders who are on record as of April 30 will have the opportunity to engage with the company during the Annual Meeting. Details regarding participation can typically be found through communication issued directly by Unicycive. To ensure that stockholders receive all necessary updates, it is advisable to keep an eye on company announcements and social media platforms where they actively share information.
Contacting Unicycive Therapeutics
For those wishing to delve deeper into Unicycive Therapeutics' developments or for any inquiries, the company has provided contact information for both investor and media relations. Kevin Gardner from LifeSci Advisors is available for investor inquiries and can be reached at kgardner@lifesciadvisors.com. Meanwhile, Rachel Visi from Real Chemistry serves as the media contact and can be contacted via redery@realchemistry.com.
The Importance of Kidney Health
Kidney health remains a topic of increasing importance, especially with the rising prevalence of kidney diseases worldwide. Unicycive Therapeutics is at the forefront of this battle, striving to offer novel interventions that can significantly impact patient care and outcomes. By focusing on innovative approaches to treatment, they play a crucial role in addressing gaps in the current healthcare landscape.
Looking Ahead
With the Annual Meeting approaching, all eyes will be on the updates and discussions that take place. Stakeholders are eager to learn about the company’s future direction and potential advancements in their product pipeline. As Unicycive continues to grow and evolve, the commitment to improving kidney health remains a top priority.
Frequently Asked Questions
What is the new time for the Annual Meeting?
The Annual Meeting will be held at 7:00 a.m., Pacific Daylight Time on June 9, 2025.
What treatments are being developed by Unicycive?
Unicycive is developing oxylanthanum carbonate for hyperphosphatemia and UNI-494 for acute kidney injury.
Who can participate in the Annual Meeting?
Stockholders of record as of April 30 are eligible to participate in the meeting.
How can I contact Unicycive for investor inquiries?
Contact Kevin Gardner at LifeSci Advisors via email at kgardner@lifesciadvisors.com.
Where can I find more information about Unicycive?
For more details, you can visit the company’s website at Unicycive.com and follow them on social media platforms.
